-

Bayer Wins Third Consecutive Trial Victory

Company has now won 13 of last 19 cases where judgments were entered at trial

WHIPPANY, N.J.--(BUSINESS WIRE)--Today Bayer won its third consecutive trial victory when a jury reached a defense verdict in its most recent trial – the Kline Roundup™ product liability trial – before Judge Ann Butchart in Philadelphia.

Separately, Plaintiffs voluntarily dismissed with prejudice the Meyer case which was at trial in the Superior Court of California for Sonoma County. These follow the defense verdict in Cody in Conway County, Arkansas, as well as a mistrial in Cloud in Delaware state court, both occurring late last week.

Bayer has now won three consecutive victories at trial, and 13 of the last 19 cases where judgments were entered at trial.

“Validating the Company’s strategy of taking cases to trial based on strong scientific and regulatory evidence, Bayer has now won three consecutive victories at trial and 13 of the last 19 cases where judgments were entered at trial,” the company said. “In these cases, the plaintiffs could not prove that Roundup™ was the cause of the injuries alleged in these cases, consistent with this science.”

The unanimous Kline verdict is the first to follow significant rulings in the Philadelphia litigation clarifying which scientific and regulatory conclusions could be admitted, a much-disputed issue in prior trials.

“While we have great sympathy for anyone who suffers a loss or injury, science proves that Roundup™ is not carcinogenic,” said the company. “We continue to stand behind the safety of Roundup™ and will confidently defend the safety of our products and our good faith actions in any future litigation.”

About Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2022, the Group employed around 101,000 people and had sales of 50.7 billion euros. R&D expenses before special items amounted to 6.2 billion euros. For more information, go to www.bayer.com.

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

Bayer


Release Versions

Contacts

Media:
Brian Leake
Brian.Leake@Bayer.com
(314) 370.3285

More News From Bayer

Bayer Starts Phase IIa Study for Treatment of Patients With Alport Syndrome

BERLIN--(BUSINESS WIRE)--Bayer announced today initiation of a Phase IIa clinical trial with BAY 3401016, an investigational monoclonal antibody with potential to block a protein called Semaphorin 3A (Sema3A), which is thought to be involved in the progression of kidney damage in Alport Syndrome (AS), a rare genetic disorder. The first-in-patient study, ASSESS, is a randomized, double-blind, placebo-controlled, group-comparison trial (NCT07211685), with an extension phase, which will investigat...

RSNA25: Pediatric Study for Bayer's Investigational MRI Contrast Agent Gadoquatrane Meets Primary and Secondary Endpoints

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer, a global leader in radiology, today revealed results from the QUANTI Pediatric study, adding to the pharmacokinetic, safety and efficacy data of the investigational low-dose MRI gadolinium-based contrast agent (GBCA) gadoquatrane. QUANTI Pediatric evaluated gadoquatrane in children with known or suspected disease undergoing contrast-enhanced magnetic resonance imaging (MRI) at a gadolinium dose of 0.04 mmol Gd/kg body weight, representing a dose reduction...

Bayer Starts New Phase III Study with Mirena® for the Treatment of Nonatypical Endometrial Hyperplasia

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced today the start of its Phase III study SUNFLOWER, an investigational study evaluating the efficacy and safety of 52mg levonorgestrel-releasing intrauterine system Mirena® for the treatment of nonatypical endometrial hyperplasia (NAEH) in women. NAEH is an abnormal thickening of the lining of the uterus, known as the endometrium, due to an imbalance between estrogen and progesterone levels. This condition is classified as nonatypical as the cells...
Back to Newsroom